V-CARMA: A tool for the detection and modification of antigen-specific T cells.
Antigens
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Genetic Engineering
/ methods
Histocompatibility Antigens Class I
/ immunology
Humans
Immunotherapy
/ methods
Lentivirus
/ genetics
Lymphocyte Activation
Lymphokines
/ metabolism
Major Histocompatibility Complex
Peptides
/ metabolism
Receptors, Antigen, T-Cell
/ genetics
Receptors, Antigen, T-Cell, alpha-beta
/ genetics
Receptors, Chimeric Antigen
/ genetics
T cell modification
peptide-MHC complex
pseudotyped lentivirus
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
25 01 2022
25 01 2022
Historique:
accepted:
13
12
2021
entrez:
19
1
2022
pubmed:
20
1
2022
medline:
1
3
2022
Statut:
ppublish
Résumé
T cells promote our body's ability to battle cancers and infectious diseases but can act pathologically in autoimmunity. The recognition of peptides presented by major histocompatibility complex (pMHC) molecules by T cell receptors (TCRs) enables T cell-mediated responses. To modify disease-relevant T cells, new tools to genetically modify T cells and decode their antigen recognition are needed. Here, we present an approach using viruses pseudotyped with peptides loaded on MHC called V-CARMA (Viral ChimAeric Receptor MHC-Antigen) to specifically target T cells expressing cognate TCRs for antigen discovery and T cell engineering. We show that lentiviruses displaying antigens on human leukocyte antigen (HLA) class I and class II molecules can robustly infect CD8
Identifiants
pubmed: 35042811
pii: 2116277119
doi: 10.1073/pnas.2116277119
pmc: PMC8795542
pii:
doi:
Substances chimiques
Antigens
0
Histocompatibility Antigens Class I
0
Lymphokines
0
Peptides
0
Receptors, Antigen, T-Cell
0
Receptors, Antigen, T-Cell, alpha-beta
0
Receptors, Chimeric Antigen
0
antigen-specific helper factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Howard Hughes Medical Institute
Pays : United States
Informations de copyright
Copyright © 2022 the Author(s). Published by PNAS.
Déclaration de conflit d'intérêts
Competing interest statement: S.J.E. is a founder of TScan Therapeutics, Maze Therapeutics, ImmuneID and Mirimus; a scientific advisory board member for Homology Medicines, TScan Therapeutics, Maze Therapeutics, and ImmuneID; and an advisor for MPM Capital.
Références
Nat Commun. 2018 Mar 12;9(1):1029
pubmed: 29531262
Nature. 2009 Mar 12;458(7235):211-4
pubmed: 19182777
PLoS One. 2008 Sep 11;3(9):e3181
pubmed: 18784843
J Biol Chem. 2010 May 28;285(22):16632-42
pubmed: 20308068
Cell. 2019 Aug 8;178(4):1016-1028.e13
pubmed: 31398327
Nat Immunol. 2019 May;20(5):652-662
pubmed: 30858620
Cell. 2020 Nov 25;183(5):1264-1281.e20
pubmed: 33091337
Mol Ther Methods Clin Dev. 2018 Oct 17;12:19-31
pubmed: 30417026
PLoS One. 2012;7(2):e31420
pubmed: 22347475
Cell. 2014 May 22;157(5):1073-87
pubmed: 24855945
Nat Commun. 2020 Sep 4;11(1):4414
pubmed: 32887877
Nat Methods. 2019 Feb;16(2):183-190
pubmed: 30700903
Cell. 2018 Jan 25;172(3):549-563.e16
pubmed: 29275860
Pharm Res. 2009 Jun;26(6):1432-45
pubmed: 19259792